TraceLink has received new funding to support its effort to expand the real-time information-sharing network in order to digitalise the global pharmaceutical supply chain.

The investment round, which was led by Georgian Partners, yielded $93m. Georgian Partners was also joined by Vulcan Capital, Willett Advisors, FirstMark Capital, Volition Capital, F-Prime Capital and Goldman Sachs.

TraceLink expects that the information sharing will create a predictable pharmaceutical supply chain.

The company will also utilise the funds for expansion into other related areas, including personalised medicine, gene therapies, predictive care, patient communities and supplier collaboration.

In addition, TraceLink intends to boost its research and development (R&D) and Services organisations.

These reinforced entities will support the company’s growing customer base of more than 930 pharmaceutical and contract manufacturers, wholesale distributors, third party logistic providers (3PL), hospitals and pharmacies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“As we continue to execute on our vision to build the digital supply chain, we are making strategic investments in machine learning, artificial intelligence and blockchain.”

TraceLink president and CEO Shabbir Dahod said: “As we continue to execute on our vision to build the digital supply chain, we are making strategic investments in machine learning, artificial intelligence and blockchain, ultimately delivering an open development platform for information sharing and predictive analytics.

“Georgian Partners’ deep expertise will significantly aid our efforts in bringing global information-sharing applications to market, driving the entire industry forward to solve critical business challenges through supply chain digitalisation.”

Georgian Partners partner Tyson Baber said: “The pharmaceutical industry is at a digital tipping point and TraceLink is in the ideal position to drive major advancements in this transformation with its information-sharing network platform.

“We are very excited to partner with TraceLink on its next phase of growth and look forward to helping guide the company on its journey to shape the future of the digital drug supply network, leveraging our experience and clients’ collective expertise in artificial intelligence and machine learning.”

The company’s network links more than 270,000 entities across the pharmaceutical supply chain.

The platform is expected to assist the life sciences industry in addressing fragmented and manual information-sharing.

Such manual sharing processes are said to result in more than $100bn annual losses due to drug diversion, revenue leakage and operational inefficiencies caused by lack of effective information exchange.